Q4 2025 saw 6% revenue and 66% EBITDA growth, led by a 28% surge in Human Health Ingredients, while consumer health declined 8%. Strategic focus is on maximizing Human Health Ingredients value, with strong guidance for 2026 and ongoing capacity expansion.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.